Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTI-PD-1 ANTIBODY AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/125289
Kind Code:
A1
Abstract:
The present invention belongs to the field of biomedicine. Provided are an anti-PD-1 antibody or an antigen-binding fragment thereof, and a biological material, a composition, a conjugate, an antibody derivative and a kit of the antibody or the antigen-binding fragment thereof, as well as the uses thereof. The anti-PD-1 antibody may specifically bind to PD-1, block interactions between PD-1 and PD-L1 or PD-L2, activate an immune response, and has good developability.

Inventors:
LI YONG (CN)
SUI RUIRUI (CN)
XI YUE (CN)
SONG FEI (CN)
JIANG DIANDONG (CN)
LEUNG STEWART (CN)
SU YUNPENG (CN)
Application Number:
PCT/CN2022/141424
Publication Date:
July 06, 2023
Filing Date:
December 23, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HC BIOPHARMA INC (CN)
International Classes:
C07K16/40; A61K35/17; A61K39/00; A61P35/00; C07K14/725
Foreign References:
CN112979802A2021-06-18
CN108290957A2018-07-17
CN107531801A2018-01-02
CN112672753A2021-04-16
CN113164621A2021-07-23
CN104411720A2015-03-11
Other References:
SUN YU-TING, GUAN WEN-LONG, ZHAO QI, WANG DE-SHEN, LU SHI-XUN, HE CAI-YUN, CHEN SHUANG-ZHEN, WANG FENG-HUA, LI YU-HONG, ZHOU ZHI-W: "PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial", AMERICAN JOURNAL OF CANCER RESEARCH, E-CENTURY PUBLISHING CORPORATION, US, vol. 11, no. 10, 15 October 2021 (2021-10-15), US , pages 5006 - 5015, XP093075965, ISSN: 2156-6976
Attorney, Agent or Firm:
SINO-CREATIVITY INTELLECTUAL PROPERTY LAW FIRM (CN)
Download PDF: